CoChat

Association between use of systemic and inhaled glucocorticoids and changes in brain volume and white matter microstructure: a cross-sectional study using data from the UK Biobank

van der Meulen, Merel, Amaya, Jorge Miguel, Dekkers, Olaf M, Meijer, Onno C · 2022 · BMJ Open
Cited by 41

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Objective: To test the hypothesis that systemic and inhaled glucocorticoid use is associated with changes in grey matter volume (GMV) and white matter microstructure. Design: Cross-sectional study. Setting: UK Biobank, a prospective population-based cohort study of adults recruited in the UK between 2006 and 2010. Participants: After exclusion based on neurological, psychiatric or endocrinological history, and use of psychotropic medication, 222 systemic glucocorticoid users, 557 inhaled glucocorticoid users and 24 106 controls with available T1 and diffusion MRI data were included. Main outcome measures: Primary outcomes were differences in 22 volumetric and 14 diffusion imaging parameters between glucocorticoid users and controls, determined using linear regression analyses adjusted for potential confounders. Secondary outcomes included cognitive functioning (six tests) and emotional symptoms (four questions). Results: Both systemic and inhaled glucocorticoid use were associated with reduced white matter integrity (lower fractional anisotropy (FA) and higher mean diffusivity (MD)) compared with controls, with larger effect sizes in systemic users (FA: adjusted mean difference (AMD)=−3.7e-3, 95% CI=−6.4e-3 to 1.0e-3; MD: AMD=7.2e-6, 95% CI=3.2e-6 to 1.1e-5) than inhaled users (FA: AMD=−2.3e-3, 95% CI=−4.0e-3 to −5.7e-4; MD: AMD=2.7e-6, 95% CI=1.7e-7 to 5.2e-6). Systemic use was also associated with larger caudate GMV (AMD=178.7 mm 3 , 95% CI=82.2 to 275.0), while inhaled users had smaller amygdala GMV (AMD=−23.9 mm 3 , 95% CI=−41.5 to −6.2) than controls. As for secondary outcomes, systemic users performed worse on the symbol digit substitution task (AMD=−0.17 SD, 95% CI=−0.34 to −0.01), and reported more depressive symptoms (OR=1.76, 95% CI=1.25 to 2.43), disinterest (OR=1.84, 95% CI=1.29 to 2.56), tenseness/restlessness (OR=1.78, 95% CI=1.29 to 2.41), and tiredness/lethargy (OR=1.90, 95% CI=1.45 to 2.50) compared with controls. Inhaled users only reported more tiredness/lethargy (OR=1.35, 95% CI=1.14 to 1.60). Conclusions: Both systemic and inhaled glucocorticoid use are associated with decreased white matter integrity and limited changes in GMV. This association may contribute to the neuropsychiatric side effects of glucocorticoid medication, especially with chronic use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2022-062446

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 52

  1. Fardet, 2014, Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events, Drugs, 74, 1731, 10.1007/s40265-014-0282-9 · DOI · Paper page
  2. 10.1136/thoraxjnl-2020-215664 · DOI
  3. 10.1176/appi.ajp.2014.13091264 · DOI · Paper page
  4. 10.1210/jc.87.5.1949 · DOI · Paper page
  5. Hou, 2020, Reversibility of impaired brain structures after transsphenoidal surgery in Cushing's disease: a longitudinal study based on an artificial intelligence-assisted tool, J Neurosurg, 1
  6. Chen, 2020, Detrimental effects of hypercortisolism on brain structure and related risk factors, Sci Rep, 10, 10.1038/s41598-020-68166-0 · DOI
  7. 10.1530/EJE-15-0600 · DOI · Paper page
  8. 10.1016/S0090-3019(99)00197-4 · DOI
  9. 10.1148/99.2.341 · DOI · Paper page
  10. 10.1210/jc.2004-2488 · DOI · Paper page
  11. 10.1016/S0006-3223(02)01750-X · DOI
  12. Jiang, 2017, Volumetric magnetic resonance imaging analysis in patients with short-term remission of Cushing's disease, Clin Endocrinol, 87, 367, 10.1111/cen.13381 · DOI
  13. Bauduin, 2020, Cortical thickness abnormalities in long-term remitted Cushing's disease, Transl Psychiatry, 10, 10.1038/s41398-020-00980-6 · DOI
  14. 10.1530/EJE-13-0471 · DOI · Paper page
  15. Toffanin, 2011, Volumetric MRI analysis of hippocampal subregions in Cushing's disease: a model for glucocorticoid neural modulation, Eur Psychiatry, 26, 64, 10.1016/j.eurpsy.2010.09.003 · DOI
  16. 10.3171/2015.7.FOCUS15257 · DOI
  17. 10.1016/j.biopsych.2003.09.010 · DOI · Paper page
  18. 10.1097/JCP.0b013e3181a3e2a7 · DOI
  19. Brown, 2019, A randomized trial of an NMDA receptor antagonist for reversing corticosteroid effects on the human hippocampus, Neuropsychopharmacology, 44, 2263, 10.1038/s41386-019-0430-8 · DOI
  20. Nguyen, 2019, The relationship between cumulative exogenous corticosteroid exposure and volumes of hippocampal subfields and surrounding structures, J Clin Psychopharmacol, 39, 653, 10.1097/JCP.0000000000001120 · DOI
  21. Brown, 2015, Hippocampal volume in healthy controls given 3-day stress doses of hydrocortisone, Neuropsychopharmacology, 40, 1216, 10.1038/npp.2014.307 · DOI
  22. van der Werff, 2014, Widespread reductions of white matter integrity in patients with long-term remission of Cushing's disease, Neuroimage Clin, 4, 659, 10.1016/j.nicl.2014.01.017 · DOI · Paper page
  23. 10.3174/ajnr.A4322 · DOI
  24. Jiang, 2017, Altered gray and white matter microstructure in Cushing's disease: a diffusional kurtosis imaging study, Brain Res, 1665, 80, 10.1016/j.brainres.2017.04.007 · DOI
  25. Pires, 2017, White matter involvement on DTI-MRI in Cushing's syndrome relates to mood disturbances and processing speed: a case-control study, Pituitary, 20, 340, 10.1007/s11102-017-0793-y · DOI
  26. Amaya, 2021, Effects of long-term endogenous corticosteroid exposure on brain volume and glial cells in the AdKO mouse, Front Neurosci, 15, 10.3389/fnins.2021.604103 · DOI · Paper page
  27. 10.1371/journal.pmed.1001779 · DOI · Paper page
  28. 10.1016/J.NEUROIMAGE.2017.10.034 · DOI · Paper page
  29. 10.1109/42.906424 · DOI · Paper page
  30. 10.1016/j.neuroimage.2011.02.046 · DOI · Paper page
  31. 10.1016/j.neuroimage.2006.02.024 · DOI · Paper page
  32. Mori S , Wakana S , Van Zijl PC , et al . MRI atlas of human white matter. Elsevier, 2005.
  33. Dekkers, 2019, Obesity, brain volume, and white matter microstructure at MRI: a cross-sectional UK Biobank study, Radiology, 292, 10.1148/radiol.2019194010 · DOI
  34. Daley-Yates, 2015, Inhaled corticosteroids: potency, dose equivalence and therapeutic index, Br J Clin Pharmacol, 80, 372, 10.1111/bcp.12637 · DOI · Paper page
  35. Wickham, 2019, Welcome to the Tidyverse, J Open Source Softw, 4, 1686, 10.21105/joss.01686 · DOI · Paper page
  36. Zeileis, 2002, Diagnostic checking in regression relationships, R News, 2, 7
  37. 10.1016/j.biopsych.2007.09.014 · DOI
  38. 10.1016/j.neuroscience.2015.07.084 · DOI · Paper page
  39. 10.1016/j.neuropsychologia.2010.06.038 · DOI · Paper page
  40. 10.1016/j.bbr.2008.11.020 · DOI · Paper page
  41. 10.1093/brain/awh729 · DOI · Paper page
  42. Savas, 2020, Systemic and local corticosteroid use is associated with reduced executive cognition, and mood and anxiety disorders, Neuroendocrinology, 110, 282, 10.1159/000501617 · DOI · Paper page
  43. 10.1002/1098-1136(200009)31:3<219::AID-GLIA30>3.0.CO;2-R · DOI · Paper page
  44. Miguel-Hidalgo, 2019, Glucocorticoid-induced reductions of myelination and connexin 43 in mixed central nervous system cell cultures are prevented by mifepristone, Neuroscience, 411, 255, 10.1016/j.neuroscience.2019.05.050 · DOI
  45. 10.1016/j.neulet.2015.03.006 · DOI
  46. van Olst, 2018, Glucocorticoid-mediated modulation of morphological changes associated with aging in microglia, Aging Cell, 17, 10.1111/acel.12790 · DOI · Paper page
  47. Freitas, 2016, Agmatine, by improving neuroplasticity markers and inducing NRF2, prevents corticosterone-induced depressive-like behavior in mice, Mol Neurobiol, 53, 3030, 10.1007/s12035-015-9182-6 · DOI
  48. Machin, 2020, The association between anxiety and disease activity and quality of life in rheumatoid arthritis: a systematic review and meta-analysis, Clin Rheumatol, 39, 1471, 10.1007/s10067-019-04900-y · DOI
  49. Pelgrim, 2019, Psychological co-morbidities in COPD: targeting systemic inflammation, a benefit for both?, Eur J Pharmacol, 842, 99, 10.1016/j.ejphar.2018.10.001 · DOI
  50. Meijer, 2018, Glucocorticoid receptor modulators, Ann Endocrinol, 79, 107, 10.1016/j.ando.2018.03.004 · DOI
  51. Van Moortel, 2020, Improved glucocorticoid receptor ligands: fantastic beasts, but how to find them?, Front Endocrinol, 11, 10.3389/fendo.2020.559673 · DOI
  52. 10.1016/j.neuroimage.2011.05.019 · DOI

Cited by

See all 41

Metadata

Authors
van der Meulen, M., Amaya, J. M., Dekkers, O. M., & Meijer, O. C.
Affiliations
Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
Venue
BMJ Open
Publisher
BMJ
Published
2022-08
Volume
12
Issue
8
Pages
e062446
ISSN
2044-6055
Cited by
41
References
18
Language
en
Funders
  • Cancer Research UK (N/A)
  • Department of Health (N/A)
  • Scottish Government (N/A)
  • Northwest Regional Development Agency (N/A)
  • Leids Universitair Medisch Centrum (N/A)
  • CONACyT (440584)
  • Welsh Government (N/A)
  • British Heart Foundation (N/A)
  • Medical Research Council (N/A)
  • Diabetes UK (N/A)
  • Wellcome Trust (N/A)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association between use of systemic and inhaled glucocorticoids and changes in brain volume and white matter microstructure: a cross-sectional study using data from the UK Biobank. https://app.cochat.ai/papers/10.1136/bmjopen-2022-062446
The paper
van der Meulen, M., Amaya, J. M., Dekkers, O. M., & Meijer, O. C. (2022). Association between use of systemic and inhaled glucocorticoids and changes in brain volume and white matter microstructure: a cross-sectional study using data from the UK Biobank. BMJ Open. https://doi.org/10.1136/bmjopen-2022-062446

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.